SAFETY/IMMUNE RESPONSE TO DNA PLASMID VACCINE IN ASYMPTOMATIC HIV

无症状 HIV 患者对 DNA 质粒疫苗的安全性/免疫反应

• 批准号: 6244440
• 负责人: ROB R MACGREGOR
• 金额: $ 2.36万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-17 至 1998-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244440
• 关键词: AIDS therapy; AIDS vaccines; HIV infections; T lymphocyte; antigen antibody reaction; cellular immunity; clinical research; clinical trial phase I; drug screening /evaluation; human subject; human therapy evaluation; immunity; outcomes research; pathologic process; vector vaccine

The primary purpose of this project is to determine whether multiple intramuscular injections of the APL 400-003 HIV DNA plasmid vaccine at dose levels of 30, 100, and 300 micrograms can be administered safely to asymptomatic HIV-infected patients. As a secondary objective, the protocol is designed to evaluate whether these multiple intramuscular injections of the APL 400-003 Vaccine might enhance existing antigen- specific immune responses, especially T cell responses, when administered to asymptomatic HIV-infected patients and to characterize the immune response profile of these patients pre- and post-injection, and to monitor indicators of progression of HIV infection in these asymptomatic HIV- infected patients.

该项目的主要目的是确定是否有多个 肌肉注射APL 400-003 HIV DNA质粒疫苗， 30、100和300微克的剂量水平可以安全地施用， 无症状艾滋病毒感染者。 作为次要目标， 方案旨在评估这些多个肌内注射是否 注射APL 400-003疫苗可能会增强现有的抗原- 特异性免疫应答，尤其是T细胞应答， 无症状的HIV感染者， 这些患者在注射前后的反应特征，并监测 这些无症状HIV感染者中HIV感染进展的指标- 感染的病人。